ATE268752T1 - Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung - Google Patents

Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung

Info

Publication number
ATE268752T1
ATE268752T1 AT00976121T AT00976121T ATE268752T1 AT E268752 T1 ATE268752 T1 AT E268752T1 AT 00976121 T AT00976121 T AT 00976121T AT 00976121 T AT00976121 T AT 00976121T AT E268752 T1 ATE268752 T1 AT E268752T1
Authority
AT
Austria
Prior art keywords
group
calcimetic
diamines
aralkyl
action
Prior art date
Application number
AT00976121T
Other languages
English (en)
Inventor
Martial Ruat
Pierre Jean-Paul Serge Potier
Robert Dodd
Philippe Marcel Dauban
Helene Veronique Faure
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE268752T1 publication Critical patent/ATE268752T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00976121T 1999-11-09 2000-11-08 Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung ATE268752T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9914050A FR2800735B1 (fr) 1999-11-09 1999-11-09 Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
PCT/FR2000/003104 WO2001034562A1 (fr) 1999-11-09 2000-11-08 Aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation

Publications (1)

Publication Number Publication Date
ATE268752T1 true ATE268752T1 (de) 2004-06-15

Family

ID=9551895

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00976121T ATE268752T1 (de) 1999-11-09 2000-11-08 Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung

Country Status (8)

Country Link
EP (1) EP1235797B1 (de)
JP (1) JP2003513954A (de)
AT (1) ATE268752T1 (de)
AU (1) AU1400801A (de)
CA (1) CA2390880A1 (de)
DE (1) DE60011462D1 (de)
FR (1) FR2800735B1 (de)
WO (1) WO2001034562A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
GB2377635B (en) 2001-04-17 2005-10-19 Hoffmann La Roche Novel use of neuronal calcium sensor-1 (NCS-1) in therapy of CNS disorders and in the development of therapeutic agents
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
DK2821067T3 (en) 2003-09-12 2017-12-04 Amgen Inc Quick solution formulation of cinacalcet
US8362274B2 (en) 2004-05-28 2013-01-29 Mitsubishi Tanabe Pharma Corporation Arylalkylamine compound and process for preparing the same
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
WO2006123020A1 (en) * 2005-05-18 2006-11-23 Juvantia Pharma Ltd Oy Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4
CA2645494C (en) 2006-03-23 2016-01-12 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
MX2008013339A (es) 2006-04-20 2009-01-26 Amgen Inc Formulaciones de emulsion estable.
EP2139462B1 (de) 2007-03-30 2014-01-22 Amgen Inc. Calcimimetische verbindungen zur verwendung bei der behandlung von darmerkrankungen
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010136035A2 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
CN102781910B (zh) * 2010-03-04 2015-03-11 味之素株式会社 烷基胺衍生物
CN102958907A (zh) 2010-06-30 2013-03-06 利奥制药有限公司 钙敏感受体激动化合物的新多晶型
CN102958908A (zh) 2010-06-30 2013-03-06 利奥制药有限公司 钙敏感受体激动化合物的新多晶型
JP2014508103A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
CN103228619A (zh) * 2010-11-26 2013-07-31 利奥制药有限公司 钙传感受体活性化合物
WO2012069421A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2280460T3 (es) * 1996-05-01 2007-09-16 Nps Pharmaceuticals, Inc. Compuestos activos frente a receptores de iones inorganicos.

Also Published As

Publication number Publication date
FR2800735B1 (fr) 2002-02-01
JP2003513954A (ja) 2003-04-15
DE60011462D1 (de) 2004-07-15
WO2001034562A1 (fr) 2001-05-17
FR2800735A1 (fr) 2001-05-11
AU1400801A (en) 2001-06-06
EP1235797B1 (de) 2004-06-09
EP1235797A1 (de) 2002-09-04
CA2390880A1 (fr) 2001-05-17

Similar Documents

Publication Publication Date Title
ATE268752T1 (de) Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung
ATE557002T1 (de) Verbindungen mit calcimimetischer wirkung
ATE89263T1 (de) Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
HUP9802323A2 (hu) Pirimidinszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények
ATE52498T1 (de) Amidderivate.
DE3873612D1 (de) Dithioacetal-verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3867403D1 (de) L-dopa-derivate oder ihre saeureadditionssalze, verfahren zu ihrer herstellung und ihre verwendung.
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
ES2038172T3 (es) Procedimiento para preparar carboxamidas heterociclicas.
ATE509910T1 (de) Vitamin d derivate mit einem 22-oxa- oder 22-thia-atom, einer sauer-, ester- oder amid- substitutierten c17-seitenkette und einer 16(17)- doppelbindung
ATE102482T1 (de) Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
ATE206926T1 (de) Verwendung eines phosphorsäurediesters zur herstellung eines arzneimittels zur behandlung von akne
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
ATE67199T1 (de) Benzoxazin-derivate und verfahren zu ihrer herstellung.
ATE196080T1 (de) Verwendung von diphenylethanderivaten zur herstellung eines arzneimittels zur behandlung von glaukom
ATE38982T1 (de) Guanidinmethylcyclohexancarbonsaeure-derivate, verfahren zur herstellung und pharmazeutische mittel.
ATE41659T1 (de) Benzothiazepinderivate, verfahren zur herstellung und pharmazeutische zusammensetzungen.
ATE69448T1 (de) Chinolincarbonsaeure-derivate, diese enthaltende zusammensetzung, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von medikamenten.
DE69325462D1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution
ATE130003T1 (de) Benzopyranderivate und verfahren zu deren herstellung.
RU94033470A (ru) Циклогексановые производные, фармкомпозиция на их основе и способ лечения
ATE47839T1 (de) N-(2,6-disubstituierte aryl)-n'pyridinylharnstoffe, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen.
DE69532963D1 (de) Verwendung von 4-acylaminopyridin derivaten zur Herstellung eines Medikaments für die Behandlung von zerebrovaskulären Erkrankungen
DE3782229D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties